Olmesartan Aurobindo Pharma (Malta) (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Aurobindo Pharma (Malta), is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to treat high blood pressure in adults.

GNH USA supplies Olmesartan Aurobindo Pharma (Malta) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil is indicated for hypertension management, acting on the renin‑angiotensin system to lower blood pressure. - Hypertension: Helps reduce systolic and diastolic blood pressure, decreasing cardiovascular risk. - Heart failure: Used as part of combination therapy to improve outcomes in patients with reduced ejection fraction. - Diabetic nephropathy: Provides renal protection by lowering intraglomerular pressure in patients with type 2 diabetes.

Adverse reactions to olmesartan may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations

When prescribing olmesartan, clinicians should consider several safety aspects. - Pregnancy: Contra‑indicated in the second and third trimesters due to risk of fetal toxicity. - Renal impairment: Monitor kidney function and adjust therapy as needed. - Hyperkalemia risk: Check serum potassium, especially when combined with potassium‑sparing diuretics. - Drug‑induced hypotension: Advise patients to rise slowly from sitting or lying positions. - Store at below 25°C: keep in the original packaging for protect against moisture.

Olmesartan can interact with several other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren: Co‑administration in diabetic patients is prohibited. - Potassium‑sparing diuretics: May cause dangerous hyper‑kalemia. - NSAIDs: Can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors: Combined use raises risk of hypotension, hyper‑kalemia, and renal dysfunction. - Lithium: May increase lithium levels and risk of toxicity. - Rifampicin: May reduce olmesartan plasma concentrations.